摘要:

Purpose of reviewDiastolic blood pressure has traditionally been considered the most important component of blood pressure and the primary target of antihypertensive therapy. However, over 30 years ago important epidemiological studies pointed out the importance of systolic blood pressure, and research during the 1990s has strengthened this view. Unlike diastolic blood pressure, systolic blood pressure increases progressively with age, and in the ageing societies elevated systolic pressure is the most common form of hypertension. The characteristic changes of systolic and diastolic blood pressure with age lead to increases in pulse pressure (systolic minus diastolic), which has emerged as a new, potentially independent risk factor. In this review we compare the relative importance of various blood pressure components.Recent findingsGenerally, in studies in which readings of systolic and diastolic blood pressure have been compared, systolic blood pressure has been a better predictor of risk. Moreover, isolated systolic hypertension predicts risk better than isolated diastolic hypertension, and the treatment of both isolated systolic hypertension and combined hypertension has reduced cardiovascular events. There are no treatment studies of isolated diastolic hypertension. Pulse pressure reflects stiffening of large arteries and is associated with several cardiovascular risk factors. Pulse pressure also predicts events in epidemiologic studies, but elucidation of an independent role is hampered by the close correlation between pulse pressure and systolic blood pressure.SummaryEpidemiological and treatment studies suggest that systolic blood pressure should be the primary target of antihypertensive therapy, although consideration of systolic and diastolic pressure together improves risk prediction. The greatest practical concern at the moment is the undertreatment of hypertension, especially systolic, and total cardiovascular risk.

ISSN:1062-4821    

出版商:OVID    

年代:2003

数据来源: OVID

摘要:

Purpose of reviewWe will summarize the latest available data on hypertension control levels in different populations throughout the world, and review the factors that appear to contribute to the widespread lack of blood pressure control in identified hypertensive patients.Recent findingsPopulation surveys throughout the world indicate that the proportion of hypertensive patients with blood pressure controlled to below 140/90 mmHg ranges from 5% in Taiwan to 25% in the United States. Studies in the US have shown that the majority of hypertensive patients classified as uncontrolled have diastolic pressure below 90 mmHg with mild systolic elevation in the 140-160 mmHg range, and that these blood pressure levels rarely elicit a treatment intensification action by the physician. The results of the Antihypertensive and Lipid Lowering to Prevent Heart Attack Trial indicate that it is feasible to maintain average blood pressures on treatment to levels well below 140/90 mmHg in elderly hypertensive patients in primary care settings. Although the literature on automated blood pressure measurement and comparisons between office blood pressure and home blood pressure continues to grow, there has been little attention paid to practicing physicians' attitudes and beliefs about different blood pressure measurement methods, or to the feasibility of standardizing blood pressure measurement in typical practice settings.SummaryThe experience in the US indicates that widely publicized treatment guidelines recommending blood pressure control targets and choice of first-line agents may have little influence on practicing physicians, even when based on solid evidence from clinical trials. Controversies in the literature regarding treatment targets, appropriate drug choices, and blood pressure monitoring methods are likely to delay improvements in overall population control.

ISSN:1062-4821    

出版商:OVID    

年代:2003

数据来源: OVID

摘要:

Purpose of reviewObesity, which has reached epidemic prevalence, is now recognized as an independent risk factor for increasing blood pressure. The complex mechanisms of obesity-related hypertension are unclear, but several studies have provided evidence of a hypertensive shift in pressure natriuresis. Excess sympathetic outflow to the kidneys and changes in renal structure and function may both affect the renal pressure relationship. Other factors that may contribute to altered natriuresis include hyperinsulinemia, hyperleptinemia and activation of the renin-angiotensin system. Disruption of the renal α2 adrenoceptors or leptin receptor implicated in natriuresis control may also be an additive risk for the increase in tubular reabsorption in obesity hypertension.Recent findingsRecent advances have highlighted the importance of two adipocyte-derived hormones - leptin and angiotensinogen - in obesity hypertension. Leptin has direct central effects that increase sympathetic outflow to the kidney and the new concept of selective leptin resistance, suggests the maintenance of leptin-induced sympathetic activation in obesity, despite resistance to leptin metabolic effects. On the other hand, a recent study showed that angiotensinogen produced in the adipocyte is also relevant to blood pressure control.SummaryThe article reviews the factors implicated in the disruption of blood pressure control in obesity. Further investigation on the time course of the disease would reveal the relative importance of each of the factors that influence the risk of hypertension in obese individuals.

ISSN:1062-4821    

出版商:OVID    

年代:2003

数据来源: OVID

摘要:

Purpose of reviewThe treatment of hypertension has been proven to reduce cardiovascular and renal risk. The role of long-acting calcium channel antagonists in the management of hypertension has been confused in the past because of a lack of controlled clinical trials on people with hypertension and in subpopulations including those with diabetes and renal disease. The year 2002 saw the publication of the results of the Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial, the largest ever prospective drug-treatment trial, which involved 33 357 people with hypertension and included a calcium-antagonist group of 9048 individuals. Major publications on blood pressure control in people with kidney disease include the African American Study of Kidney Disease and Hypertension, and publications on people with diabetes include the results of the normotensive arm of the Appropriate Blood Pressure Control in Diabetes trial.Recent findingsThe main finding, from the studies reported in the last year, is that blood pressure control can be achieved using one or more of the first-line agents, including diuretics, calcium antagonists and angiotensin-converting enzyme inhibitors. On the basis of the Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial, diuretics make clinical and economic sense as initial therapy for those with hypertension. Calcium antagonists are well tolerated and effective and should be considered as the initial drug therapy when diuretics are not tolerated or when multiple drug therapy is indicated. Angiotensin-converting enzyme inhibitors should be used in people with nephropathy, and, in these patients, will nearly always need to be part of multiple drug therapy to achieve blood pressure control. When blood pressure control can be achieved in largely non-nephropathic populations, there is further evidence that the drug class used as initial therapy may not be important. One of the main themes coming from the literature in the last year is that renal function is increasingly being recognized as an important outcome measure and marker of cardiovascular risk.SummaryThe focus in blood pressure management must now be on identifying those with hypertension and bringing their blood pressure to target. For the majority of those with hypertension and renal disease, multiple drug therapy will be required, and, to achieve blood pressure targets, calcium antagonists are an appropriate part of this regimen. Particular attention is needed for nephropathic patients because of their higher risk of progression and the need for combination therapy; this group is likely to be the focus of future research and publications.

ISSN:1062-4821    

出版商:OVID    

年代:2003

数据来源: OVID

摘要:

Purpose of reviewTo summarize recent trends in the prevalence of nephropathy due to diabetes and to assess the causes of these changes. Such analysis may influence our strategy to reduce the increasing numbers of cases.Recent findingsRegistry data show a progressive increase in the number of cases of nephropathy due to type 2 diabetes such that diabetes is now the leading cause of end-stage renal failure. Despite the increasing incidence of type 1 diabetes, European data indicate the numbers of type 1 patients going on to dialysis are stable. The increase in the prevalence of type 2 diabetes, which in itself is related to increasing levels of obesity, is a major factor but the increase in end-stage renal failure is disproportionately greater. Other factors are therefore important such as earlier development of diabetes and better prevention of coronary events. Similar changes are occurring worldwide. Clinical predictors and genetic markers are being studied.SummaryMore active management of proteinuric type 2 diabetic patients is required to achieve the demanding targets recommended on the basis of clinical trial data. However, the figures suggest that only widespread application of public health measures aimed at the epidemic of type 2 diabetes itself will prevent further rapid escalation of the numbers of type 2 patients reaching end-stage renal failure.

ISSN:1062-4821    

出版商:OVID    

年代:2003

数据来源: OVID

ISSN:1062-4821    

出版商:OVID    

年代:2003

数据来源: OVID